Lung cancer is one of the most common malignancies with high incidence and mortality rates, and its incidence continues to rise due to factors such as increased atmospheric pollution and smoking. The lung is also the most frequent site of metastasis for other malignant tumors. The first choice of treatment for lung cancer and metastatic lung cancer is surgical resection, however, less than 30% of patients have the chance of surgical resection. Other treatments commonly used include systemic chemotherapy and radiotherapy, which have certain efficacy, but all have disadvantages such as long course, large side effects and high cost. To a certain extent, bronchial artery infusion chemotherapy overcomes the shortcomings of systemic intravenous chemotherapy and improves the treatment effect of lung cancer. Lung cancer is mainly supplied by bronchial artery, and many lung metastases are also supplied by bronchial artery, which is the theoretical basis of transbronchial artery perfusion chemotherapy for lung cancer and lung metastases. Compared with systemic transvenous chemotherapy, transbronchial artery infusion of chemotherapeutic drugs enables the drugs to act directly on the tumor first without going through systemic hemodilution and liver metabolism, and the concentration of chemotherapeutic drugs in the tumor can reach tens of times that of intravenous chemotherapy, thus significantly improving the killing ability of tumor cells. Therefore, the side effects such as nausea, vomiting and bone marrow suppression are reduced, and the medical cost is also reduced. Bronchial artery infusion chemotherapy is performed by puncturing the femoral artery at the root of the thigh, introducing a very thin catheter (about 2mm in diameter), inserting it into the bronchial artery on the side of the lesion under X-ray fluoroscopy, and then infusing chemotherapy drugs after the blood supply to the tumor is clearly identified by imaging. Bronchial artery embolization improves the efficacy of perfusion chemotherapy and is particularly effective for recurrent hemoptysis caused by lung cancer. Bronchial artery perfusion chemotherapy/embolization usually needs to be done 2-3 times with 4-6 weeks interval each time, and the cost of one time is around $15,000. This treatment is generally very safe. A particularly serious complication is spinal cord injury, often caused by high concentrations of contrast agents, chemotherapy drugs or embolization particles entering the blood supply arteries of the spinal cord and causing spinal cord ischemia. Patients may experience numbness, weakness or urinary and defecation disorders in the limbs, which can lead to paraplegia in severe cases.